Kamuvudine-9 · Researchers tested K-9, a modified nucleoside that blocks an inflammation-related cell alarm, in a mouse model of MS. The experiments examined vision, movement, nerve cells and myelin.
Researchers tested K-9, a modified nucleoside that blocks an inflammation-related cell alarm, in a mouse model of MS. The experiments examined vision, movement, nerve cells and myelin.
No clinical study in MS is established
For MS, findings are from animal models; the human K-9 eye-disease study does not establish a clinical study in MS.
The paper reports recovery of some existing vision and movement problems in mice and protection of nerve cells and myelin. This is animal evidence. Separate insurance analyses found associations involving other NRTI medicines; those are not studies of K-9 and do not show that K-9 works in people with MS. K-9 has also been studied in eye disease, which does not establish an MS study.
K-9 is not an MS treatment. No clinical study of K-9 for MS is established, and the animal findings do not show benefit in people.
The paper reports that K-9 limited and reversed some vision and movement problems in mice with experimental autoimmune encephalomyelitis, an MS model, and preserved nerve cells and myelin. A separate insurance-data analysis in the paper concerns other NRTI medicines, not K-9.
Source: Science Translational Medicine — peer-reviewed primary article ↗Source: NIH summary (animal findings and separate NRTI analysis) ↗